Search PubMed⌕ Search

Biomedical subjects

U Bruntsch

Publications and source records attributed to U Bruntsch.

At least 73 records · Page 4Linked to original sources
PubMed1979

[Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)].

In a randomised, multicentre study the effect of changing the combined cytostatic treatment with VAC (vincristin, adriamycin, cyclophosphamide) to FMC (fluorouracil, methotrexate, cyclophosphamide) was tested, as well as the effect of active non-specific immune stimulation with Corynebacterium parvum, and compared with a control group. In 59 of 120 patients (49%) in whom the results could be analysed there was a measurable significant regression of tumour size to less than 50% of its initial value. The course was stabilized in a further 43 (36%) women. Further tumour-growth progression or death in the early phase of treatment occurred in only 18 women (15%). Average remission was 16 months. Median survival time from start of the study in all analysable patients averaged 22 months. Patients with an ulcer at the site of application of Corynebacterium parvum had a clearly prolonged survival time. In all, immune stimulation with Corynebacterium parvum was no better, either with regard to the remission rate, remission duration or survival time.

Breast Neoplasms↗
PubMed1977

[Primary and secondary exploratory laparotomy and splenectomy in Hodgkin's disease (author's transl)].

Exploratory laparotomy with splenectomy was performed on 275 patients with hisologically confirmed Hodgkin's disease. In 188 patients the laparotomy was a primary one to determine more precisely the state of the disease. A secondary laparotomy was performed in 87 patients 1-12 years after diagnosis and radiotherapy. In 17.5% of patients the state had to be revised after laparotomy with splenectomy. In 38 the disease had further progressed, while in ten it had slighty regressed. In four cases clinical stage I proved to be stage III. Even prognostically more favourable forms may have progressed at first diagnosis. There was no correlation between B-symptoms and histological type, but there was between B-symptoms and spread of the disease. Calculated spleen weight provided no clue as to spleen involvement. There was no clear relationship between spleen involvement and histological subclassification. Risk-effect analysis indicate that laparotomy with splenectomy was useful because it makes optimal treatment possible.

Adult↗
PubMed1977

[Chemotherapy of malignant bone tumors].

In several primary malignant tumors significant improvement of formely bad prognosis has been achieved by the introduction of new cytostatic compounds and the study of new cytostatic combination regimens. Adjuvant chemotherapy in osteosarcoma and Ewing's sarcoma led to remarkable increase in survival rates. Leaning on natural history and on remission rates reached by cytostatic treatment in metastasizing stages of disease, proposals for adjuvant chemotherapy are made and chemotherapy regimen appliable on out-patient basis is described.

Antineoplastic Agents↗
PubMed1977

[Chemotherapy of the ovarian carcinoma (author's transl)].

Ovarian carcinomas are highly sensitive to chemotherapy. The alkylating agents were most extensively investigated. With these drugs remissions can be obtained in about 50% of the patients. Some early results seem to show a higher response rate and a longer duration of remission after combination chemotherapy. In ovarian carcinoma it has to be the aim of the chemotherapy to obtain a complete remission. The indications for chemotherapy are not yet well defined. Treatment is definitely indicated in stage IV (FIGO) or in recurrent disease after radiotherapy. This treatment has to be given as a long-term therapy over a long period of time. In stage III and II b disease a combined treatment plan has to be developed by the radio- and chemotherapist. At the present time no data are available which prove or disprove the value of an adjuvant chemotherapy in the early stages of ovarian carcinoma. Remembering the somewhat promising results of adjuvant chemotherapy in breast cancer, it is conceivable that prophylactic chemotherapy will prove to be indicated in early stages of ovarian carcinoma.

Altretamine↗
PubMed1977

[Chemotherapy in bronchogenic carcinoma (author's transl)].

Therapy results in bronchogenic carcinoma remain unchanged since the establishment of thoracic surgery. Prognosis depends on the two main factors: histological type and extension of disease at the time of diagnosis. Both factors are mutually dependent. Small cell carcinoma of the bronchus represents a special entity with its early hematogenous spread and the poorest prognosis of all bronchogenic carcinomas. The tumor is highly sensitive to radioor chemotherapy. A marked prolongatoion of medium survival time can be obtained by combination chemotherapy. This is usually accompained by an obvious improvement in the patient's general condition. In certain cases results can be further improved by irradiation of the primary tumor and the mediastinum. Prophylactic cranial irradiation is often indicated because of the frequent cerebral metastases. Results of chemotherapy are much less impressive in adenoor squamous-cell carcinomas of the bronchus. Such therapy can only be recommended for the exceptional case. Pilliative radiotherapy should be used freely. Till now, adjuvant chemotherapy after surgery has only proven its value in small cell bronchogenic carcinoma.

Antineoplastic Agents↗
PubMed1976

[Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].

In 18 patients with advanced Hodgkin's disease, refractory to previous 'C-MOPP' treatment, a new therapeutic protocol of adriamycin, DTIC, CCNU and bleomycin was introduced. Three patients who had previously failed to respond to any other chemotherapy failed also to respond to the new one. But two complete and 11 partial remissions were obtained in the other 15 patients who had previously responded to C-MOPP before becoming refractory to it. Two patients had further progression of the disease during the new treatment.

Adult↗
PubMed1976

[cis-Diamino-dichloro-platinum (II) in the treatment of otherwise treatment-resistant malignant testicular teratoma (author's transl)].

cis-Diamino-dichloro-platinum (II) (DDP, NSC-119875) is an inorganic compound with cytostatic properties which have only recently been appreciated. DDP has an action which may tentatively be described as alkylating through some, as yet unknown, metabolic product. In a phase I study the effectiveness against testicular neoplasma had been established. A prospective trial was, therefore, conducted to test the drug's efficiency in patients with disseminated non-seminomatous testicular cancer refractory to all previously used combinations of chemotherapy. In a group of 22 patients the results were: 1 CR, 14 PR, 2 NC, and 5 PD. Because of these results, DDP was made part of an induction regime for disseminated and non-seminomatous testicular tumors.

Adolescent↗